Airlines can take control of the payments experience for both direct and in-direct channels

Move improves cashflow and loyalty for airlines by directly processing UnionPay cards

SHANGHAI, March 12, 2026 /PRNewswire/ — According to ResearchAndMarkets’ recent forecasts, Chinese outbound travel is predicted to grow at a Compound Annual Growth Rate (CAGR) of 13.5%, increasing from $140B today to reach $386B by 2033. UnionPay International helps cardholders to easily make cross-border payments in 183 markets and its payment methods are particularly popular with travelers across Asia Pacific. That’s why being able to directly accept UnionPay cards is crucial for airlines serving travelers from the 85 countries and regions where UnionPay cards are issued.

Under the terms of a new partnership between Outpayce from Amadeus and UnionPay International, airlines that power online payments in their direct channels with Outpayce’s Xchange Payments Platform can natively accept UnionPay cards in the standardized way. This native acceptance secures more revenue for airlines while improving the payment experience for travelers by drastically increasing acceptance rates.

The Amadeus Travel Platform is a comprehensive marketplace connecting travel providers like airlines, hotels, car rentals and rail operators to more than 60,000 travel sellers so they can combine and retail attractive offers. Thanks to the new partnership, travelers wishing to pay with a UnionPay card can be passed through to the provider to pay directly when making a booking.

The new approach means travelers can access the same payments experience as an airline offers on its website, including access to loyalty benefits that depend on making payment directly with the airline.

By directly processing the payment, airlines improve cash flow by accessing funds faster and can also take control of the payments experience for indirect bookings. By applying their own approach to issues like fraud management, airlines can improve acceptance rates and deliver a better overall experience.

Bomme Sheng, Global Director of UnionPay International said: “UnionPay has established a solid presence in the airline payment vertical. By deepening cooperation with Amadeus, UnionPay cards will be fully integrated into the underlying technology of airline distribution, covering websites, and indirect channels. This will further refine UnionPay’s air travel payment ecosystem and promote the industry to upgrade towards greater efficiency and diversity.”

Damian Alonso, Head of Product and Partnerships, Outpayce said: “We are committed to enabling a smooth payment experience in every channel however the traveler chooses to pay. Our payment platform approach means travelers can pay with the method of their choice in a way that’s easy and trusted. Airlines can now offer the same payments experience to UnionPay cardholders whether they are shopping via Amadeus travel sellers or in their own direct channels, maximizing investments in payments and improving the overall experience.”

The addition of card acceptance for UnionPay means that travelers can pay travel providers directly with all major card schemes when their booking is completed via the Amadeus Travel Platform. Native acceptance of UnionPay cards via the Outpayce Exchange Payments Platform is expected to be enabled in H1 2026 and will be enabled gradually across different markets throughout 2026 within the Amadeus Travel Platform.

Notes to the editors:

About UnionPay International

UnionPay International (UPI) is dedicated to expanding UnionPay’s global network and building seamless cross-border payment experiences. In partnership with over 2,600 partners worldwide, UPI enables card acceptance in 183 countries and regions with issuance in 85 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.

About Outpayce

Amadeus makes the experience of travel better for everyone, everywhere by inspiring innovation, partnerships and responsibility to people, places and planet. As a wholly-owned company, Outpayce from Amadeus is the next step in scaling the Amadeus payments business with fresh investment in talent, an open API platform and a license to deliver new regulated payment services.

Outpayce delivers smoother end-to-end travel experiences making travel payments simple. Our open platform connects FinTech and banking service providers to the entire travel ecosystem, allowing customers and travelers to easily benefit from new advances in payments.

Outpayce Xchange Payment Platform (XPP) solves challenges in areas like authentication, acceptance and foreign exchange (FX) for travel merchants and gives access to partners that resolve areas like fraud management and authentication to offer a smoother overall experience for the traveler. 

In the B2B payments space, Outpayce orchestrates payments with a range of virtual cards, currencies and payment methods to optimize cost, acceptance and agility wherever a travel seller needs to pay a supplier.

Outpayce delivers an end-to-end experience by continuing to work with all Amadeus’ teams and embedding its capabilities in all of Amadeus’ applications. The future is travel simply paid. 

To find out more about Outpayce, visit www.outpayce.com.

Follow us on: LinkedIn

Source

WUXI, China, March 12, 2026 /PRNewswire/ — LabConnect, a leading provider of technology-driven central laboratory services and functional service provider solutions for clinical trials, today announced the grand opening of its new facility in Wuxi, China. As clinical trials become increasingly global and complex, sponsors are seeking laboratory partners that can provide integrated testing, logistics and data oversight across regions. Together with LabConnect’s laboratory capabilities in Australia, the new site strengthens the company’s ability to support multi-regional clinical trials while helping Asia-Pacific pharmaceutical, biotechnology and clinical research organizations expand their research programs globally.

Fully integrated into LabConnect’s global infrastructure, the Wuxi facility enables study teams to operate across regions with unified data, consistent operational oversight and advanced sample logistics and handling procedures.

The facility was developed in collaboration with Teddy Laboratory, now part of Frontage Laboratories, combining Teddy Laboratory’s local laboratory expertise with LabConnect’s global central laboratory services, logistics capabilities, and technology-driven decentralized network model.

“This facility reflects LabConnect’s continued investment in building the global services needed to support clinical trials today and the next generation of clinical research,” said Wes Wheeler, Chief Executive Officer of LabConnect. “We are proud to offer China-based capabilities and a global service network that supports both multinational pharmaceutical and biotechnology companies entering China and Chinese companies expanding into international markets.”

The Wuxi facility will support a range of clinical trial services, including custom kit building, advanced sample tracking and logistics, and biorepository services, all designed to meet international regulatory standards.

The grand opening event, held today at the facility in the Xinwu District of Wuxi, included a ceremonial ribbon cutting, guided laboratory tours and presentations highlighting LabConnect’s technology-driven approach to central laboratory services. Representatives from LabConnect, Teddy Laboratory, government officials, and members of the regional clinical research community attended the event.

With the addition of the Wuxi site, LabConnect now operates eight global locations, enabling sponsors and CROs to rely on a single partner for central laboratory services across studies of any size or geographic complexity.

About LabConnect
LabConnect is a global provider of technology-driven central laboratory services and functional service provider solutions for pharmaceutical, biotechnology and contract research organizations. The company connects laboratories, logistics, technology and scientific expertise through a decentralized laboratory network model to deliver integrated solutions for clinical trials worldwide. Learn more at www.labconnect.com.

Source

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, March 11, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on March 11th

• Equities remain choppy as the conflict in the Middle East continues and the International Energy Agency is proposing the biggest-in-history release of emergency oil reserves.
• Inc. unveiled its 2026 Female Founders 500 list yesterday, honoring dynamic women business leaders.
• Entrepreneurs First announced earlier that it raised $200 million to support the next generation of builders, with contributions from investors including Reid Hoffman and Eric Schmidt.
• U.S. Antimony (NYSE: UAMY) Chairman and CEO Gary Evans will join NYSE Live this morning to explain the company’s critical role in defense applications.  

Opening Bell
U.S. Antimony (NYSE: UAMY) celebrates its uplisting to the NYSE

Closing Bell
Costamare Bulkers (NYSE: CMDB) celebrates its 2025 spin-off

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Bunge CEO Greg Heckman hosted its investor day at NYSE

Source

ROME, March 11, 2026 /PRNewswire/ — Haier Biomedical recently convened its European Partner Summit in Rome under the theme “Advancing Together – Sharing the Future of Biomedical Innovation,” which brought together 37 regional partners and industry leaders from 23 European countries to outline its long-term commitment to Europe and unveil a broadened laboratory solutions portfolio, marking a strategic upgrade of its brand portfolio. New strategy shifts toward scenario-based, application-driven solutions, while sharing its long-term plan to deepen localization in Europe and deliver more comprehensive, tailored services and support across the region.

At the summit, Enrique Wang, Global Market Director of Haier Biomedical, reaffirmed the Company’s global vision to achieve over 50% of global revenue from international markets by 2027 and over 50% revenue contribution beyond refrigeration by 2028. He emphasized that Europe remains a strategic priority within the company’s globalization roadmap, which underscores the “In Europe, for Europe” localization principle of delivering products, services, and support tailored for regional regulatory standards, customer expectations, and application needs.

Outlining the 2026 European strategy, Semir Selimovic, director of North, Central & Eastern Europe of Haier Biomedical Europe, highlighted continued investment in local sales, service, and product expertise to strengthen responsiveness and execution across key markets. Europe has become one of Haier Biomedical’s fastest-growing international regions, and this is supported by expanding local teams and a steadily broadening product portfolio.

Expanding from freezers to full solutions

Among the newly introduced products, the Plasma Apheresis System XJ-III drew particular attention. The system has obtained EU MDR certification, which marks a significant milestone in meeting Europe’s stringent regulatory requirements and strengthens Haier Biomedical’s position in blood and plasma technology. Across Europe, Haier Biomedical’s CO₂ incubators, centrifuges, biosafety cabinets, and cold storage lines continue to gain market share, supported by energy-efficient technologies and compliance with regional certification standards. The product evolution presented in Rome demonstrates a move toward unlocking a full portfolio capable of supporting laboratories, hospitals, and life science institutions with end-to-end solutions.

Automation and intelligent blood management as growth engines

Daniele Pericolini, European Automation Solution Specialist of Haier Biomedical, outlined the Company’s strategy to drive future growth through laboratory automation and intelligent blood management systems. Haier Biomedical’s automated biobank solutions integrate RFID-enabled ultra-low temperature storage, modular automation platforms, and liquid nitrogen systems to enhance sample traceability and operational efficiency. By addressing challenges such as sample integrity, temperature tracking, and high-density storage, the Company has positioned itself within Europe’s growing demand for advanced biobanking infrastructure.

Additionally, the U-Blood intelligent blood management system represents a shift from traditional cold storage to real-time connected blood supply chain management. Designed to reduce wastage, improve traceability, and support round-the-clock transfusion workflows, the solution aligns with Europe’s increasing focus on safety, digitization, and zero-waste healthcare initiatives.

European customer recognition and brand alignment

The summit also featured success stories from four European partners representing Germany, Slovakia, France, and Denmark, which highlighted strong local validation of Haier Biomedical’s solutions. In France, long-term partner showcased the jointly developed biosafety cabinet adapted to French standards, with over 230 units deployed across over 100 customers. In Denmark, Haier Biomedical partner shared its ultra-low temperature freezer success through public tenders and ongoing expansion into additional product categories. In Slovenia, large-scale pharmaceutical installations reinforced the Company’s capabilities in managing complex, multi-unit projects. Partners from Central Europe also emphasized reliability, regulatory compliance, and after-sales support as key differentiators.

Strong international growth performance in 2025

Haier Biomedical’s expanding European footprint is supported by a solid financial performance. In 2025, the Company reported revenue exceeding RMB 2.3 billion, with international revenue reaching RMB 840 million, which accounts for over 36% of total revenue and reflects continued global expansion.

Europe recorded double-digit growth, which contributed to a large portion of overall international revenue growth. The Company’s AI-driven and automation-related solutions contributed approximately 15% of total revenue in 2025, which signalled accelerating technology-driven transformation. These results reflect a broader shift from hardware exports toward localized solution delivery supported by regional teams and certifications across over 18 countries.

As the European Partner Summit concluded, Haier Biomedical reaffirmed its commitment to strengthening localized operations, expanding automation and life science solutions, and advancing collaborative growth with partners. Through a combination of global innovation capabilities and local execution in Europe, the Company aims to further consolidate its position as a trusted life science solutions provider in 2026 and beyond.

For more information, please visit https://www.haiermedical.com/.

Source

Source: Beijing Tsingke Biotech Co., Ltd.

Source

SYDNEY, March 10, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III AMPLIFY trial (NCT06970847)^[1] has now consented  in excess of the planned number of participants following strong demand for study participation at sites in the United States (US) and Australia. Consenting of new patients has stopped at all sites pending completion of remaining screening assessments and confirmation of final enrolment numbers.

AMPLIFY (⁶⁴Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer) is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of ⁶⁴Cu-SAR-bisPSMA positron emission tomography (PET) in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment at clinical sites across the US and Australia.  

The aim of this registrational study is to investigate the diagnostic ability of ⁶⁴Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer in men with PSA levels above 0.2 ng/mL. Evaluation will be across two imaging timepoints: Day 1 (1-4 hours post-administration, same-day imaging) and Day 2 (approximately 24 hours post administration, next-day imaging).

AMPLIFY commenced in May 2025, seeking to enrol approximately 220 participants, and the first trial participant was imaged in the same month at XCancer with Dr Luke Nordquist (Omaha, NE). The data from this study will complement the Phase I/II COBRA^[2] and Phase II Co-PSMA^[3] trials. Both studies have demonstrated enhanced imaging capabilities of ⁶⁴Cu-SAR-bisPSMA over standard-of-care (SOC) prostate-specific membrane antigen (PSMA) PET imaging in patients with biochemical recurrence (BCR) of prostate cancer. As a pivotal trial, the final study results from AMPLIFY are intended to provide evidence to support an application to the US Food and Drug Administration (FDA) for approval of ⁶⁴Cu-SAR-bisPSMA as a new diagnostic imaging agent in BCR of prostate cancer.

⁶⁴Cu-SAR-bisPSMA is also currently being evaluated in another registrational Phase III trial, CLARIFY (NCT06056830)^[4], which is expected to close recruitment in CY2026. Building on the Phase I PROPELLER^[5] study, the objective of CLARIFY is to assess the diagnostic performance of ⁶⁴Cu-SAR-bisPSMA PET across same-day and next-day imaging in detecting prostate cancer within the pelvic lymph nodes in patients who are scheduled to undergo radical prostatectomy and pelvic lymph node dissection. The CLARIFY results are intended to support an FDA approval application for ⁶⁴Cu-SAR-bisPSMA in prostate cancer patients who are candidates for definitive therapy.

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, “We are about to enter the realm of a select few Australian companies who have developed a drug at the benchtop of Australian science and completed an international Phase III clinical trial with that drug, taking us one step closer to commercialisation. Our team is excited to have reached this initial recruitment milestone in the AMPLIFY trial in just 9 months since we imaged our first participant in the study. This is no small feat, given we achieved this phenomenal pace of recruitment despite three SOC products already in the market, commercialised by four different companies.

“True to our commitment to the highest standards of clinical research, we recruited participants at numerous different sites across the US and Australia to ensure the trial reflected the broad patient population, real-world clinical settings and various PET cameras in which this product is intended to be used. This strategy required careful planning to allow for all participating sites to contribute to the recruitment, based on allocation of participant numbers to be enrolled per site, resulting in what we believe will be a robust and well-balanced dataset and supporting the integrity and quality of the AMPLIFY study.

“Despite the variations in the sites’ activation times, the speed of enrolment in this trial not only highlights the unmet need in the BCR space but also indicates the strong demand for ⁶⁴Cu-SAR-bisPSMA from clinicians and patients seeking more effective and accurate prostate cancer detection diagnostics. With persistent outreach from participating sites to enrol more patients, clinicians and patients would rather use an unapproved product, undertaking additional demands of a clinical trial, than rely on the findings of the current SOC PSMA PET.

“To date, we have imaged approximately 600 patients with prostate cancer with ⁶⁴Cu-SAR-bisPSMA, and just in the last year we scanned over 350 of them. The growing demand for better imaging is driven by so many men around the world with prostate cancer who seek accurate and timely identification of disease location and recurrence. We are committed to answering these needs of patients, clinicians and imaging facilities with a next-generation diagnostic imaging agent specifically designed to deliver significant benefits in efficacy, clinical management, quality of life and operational flexibility across the prostate cancer care pathway.

“The results on ⁶⁴Cu-SAR-bisPSMA generated to date, from our initial discovery and pre-clinical work, to the recently announced Co-PSMA and the COBRA trials, constitute an extensive body of evidence against SOC, demonstrating that maximal clinical benefit of PSMA PET can be derived through the combination of the proprietary SAR-bisPSMA agent and optimised imaging timepoints facilitated by the half-life of copper-64. Achieving a two to three times improvement in lesion detection over SOC in BCR is an incredible achievement. We believe we can grow the blockbuster PSMA PET market even further with a product that has shown impressive efficacy in clinical trials coupled with many logistical and supply chain benefits. Our team will be working closely with our vendors and participating sites to advance the final data package and with regulatory authorities to get this product to patients in need as soon as possible.

“We also look forward to closing recruitment in the CLARIFY trial this year and progressing our theranostic Phase I/IIa SECuRE trial towards completion. Together with three Fast Track Designations we have for SAR-bisPSMA and positive interactions with the US FDA to date, these milestones place us closer than ever to commercialisation of this exciting agent through the entirety of the prostate cancer journey, from first detection to late-stage metastatic disease.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

Disclaimer

⁶⁴Cu-SAR-bisPSMA and ⁶⁷Cu-SAR-bisPSMA are unregistered products. Their safety and efficacy have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[6]. Prostate cancer is the second-leading cause of cancer death in American men. The American Cancer Institute estimates there will be about 333,830 new cases of prostate cancer in the US in 2026 and around 36,320 deaths from the disease^[7].

For more information, please contact:

References

1. ClinicalTrials.gov Identifier: NCT06970847. https://clinicaltrials.gov/study/NCT06970847 
2. Nordquist et al. COBRA: Assessment of safety and efficacy of ⁶⁴Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy. EANM, 2024.
3. Clarity Pharmaceuticals. Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial. https://www.claritypharmaceuticals.com/news/abstract-eau-2026/
4. ClinicalTrials.gov Identifier: NCT06970847. https://clinicaltrials.gov/study/NCT06907641
5. Veronica Wong, Nat Lenzo, Michelle Parker and Louise Emmett. ⁶⁴Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer. JCO 41, 5039-5039(2023). DOI:10.1200/JCO.2023.41.16_suppl.5039
6. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
7. American Cancer Society: Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.

Source